Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

This is a comperative study of Capecitabine Capsule 500 mg tablets manufactured by sponsor with Xeloda 500 mg Tablets of Genetech USA, A Member of Roche group, USA, in adult patients with Breast cancer and Colorectal cancer under fed condition.

ABSTRACT: Intervention1: Capecitabine Capsule 500 mg Tablets: Dose: 2500 MG/m2/Day for 14 days Duration : 1 cycle Frequency : 14 days with 7 days rest period. Mode of Admin: oral Control Intervention1: Capecitabine Capsule 500 mg Tablets: Dose: 2500 MG/m2/Day for 14 days Duration : 1 cycle Frequency : 14 days with 7 days rest period. Mode of Admin: oral Primary outcome(s): To compare and evaluate the single-dose oral bioavailability of Capecitabine Tablets, USP 500mg manufactured by Amneal Pharmaceuticals, USA with Â (capecitabine) Tablets 500mg distributed by Genentech USA, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990, following a single oral 2000mg (4x500mg) dose administration in adult human patients with cancer under fed condition.Timepoint: 0.17, 0.33, 0.50, 0.67, Pre, dose0.83, 1.00, 1.25, 1.50, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 7, and 8 following drug administration in each period.

DISEASE(S): Breast Cancer And Colorectal Cancer

PROVIDER: 2573649 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A comparative study of Capecitabine Capsules 500 mg and Capecitabine tablet 500 mg in patients of breast, colon or rectal cancer

Project description:Intervention1: Capecitabine Extended Release Capsules 500 mg of Intas Pharmaceuticals Limited, India: Dose: 1250 mg/m2; Frequency: twice daily; Mode of Administration: Per oral; Duration of treatment: 1 week Control Intervention1: Capecitabine film coated tablets 500 mg of Accord healthcare Inc, USA: Dose: 1250 mg/m2; Frequency: twice daily; Mode of Administration: Per oral; Duration of treatment: 1 week Primary outcome(s): To compare the bioavailability and characterize the pharmacokinetic profile of the Sponsors formulation- Capecitabine Extended Release Capsules 500 mg (Test drug, Intas Pharmaceuticals Ltd., India) with Capecitabine) film coated Tablets 500 mg (Reference drug, Intas Pharmaceuticals Ltd., IndiaTimepoint: Pre-dose (Day01, Day 05 to Day 07 and Day 08 Day 12 to Day 14) Post-dose on Day 07 and Day 14

| 2582199 | ecrin-mdr-crc

A study comparing capecitabine oral granules 500 mg per packet to capecitabine tablets 500 mg in patients with breast cancer or colorectal cancer

Project description:Intervention1: Capecitabine oral granules 500 mg per packet of Intas Pharmaceuticals Limited, India: Dose: single dose as multiples of 500 mg ; Frequency: single dose on day 1, day 2 and day 3 ; Mode of Administration: oral ; Duration of treatment: 3 days Control Intervention1: XelodaÂ (capecitabine) tablets 500 mg, Distributed by: Genentech USA, Inc., A member of the Roche group: Dose: single dose as multiples of 500 mg ; Frequency: single dose on day 1, day 2 and day 3 ; Mode of Administration: oral ; Duration of treatment: 3 days Primary outcome(s): To characterise the pharmacokinetic profile of the sponsors test formulation [capecitabine oral granules 500 mg per packet (Manufactured by Intas Pharmaceuticals Ltd, India)] relative to that of reference formulation [XelodaÂ (capecitabine) tablets 500 mg (Distributed by: Genentech USA, Inc., A member of the Roche group, 1 DNA Way, South san Francisco, CA 94080-4990)] in patients of metastatic breast cancer or metastatic colorectal cancer under fed condition and to assess the bioequivalence.Timepoint: Pre-dose and 0.167, 0.333, 0.500, 0.750, 1.000, 1.250, 1.500, 1.750, 2.000, 2.250, 2.500, 2.750, 3.000, 3.333, 3.667, 4.000, 4.500, 5.000, 6.000, 7.000 and 8.000 hour post-dose

| 2592359 | ecrin-mdr-crc

A Clinical trial intended to compare two formulations of Capecitabine tablets, in patients with Breast Cancer or Colorectal Cancer.

Project description:Intervention1: Capecitabine Manufactured by Mylan Pharmaceutical Inc., USA: Each patient will receive a Capecitabine 1250 mg/m2 administered twice daily orally :BD (morning and evening; equivalent to 2500 mg/m2 total daily dose)for 14 days. The dose will be comprised of multiples of the 500 mg tablet Control Intervention1: XELODAÂ (Capecitabine 500 mg) tablets: capecitabine tablets in the doses of 2500 mg/m2/day in two divided dose i.e. in morning and evening Control Intervention2: XELODAÂ (Capecitabine 500 mg) tablets.: XELODAÂ 500 mg tablets, Manufactured by Genentech US Inc. USA).Each patient will receive a Capecitabine 1250 mg/m2 administered twice daily orally :BD (morning and evening; equivalent to 2500 mg/m2 total daily dose)for 14 days. The dose will be comprised of multiples of the 500 mg tablet. Primary outcome(s): To characterize the pharmacokinetic profile of the sponsors test formulation (Capecitabine Tablets 500 mg, Manufactured by Mylan Pharmaceutical Inc., USA) relative to that of reference formulation (XELODAÂ 500 mg tablets, Manufactured by Genentech US Inc. USA) in patients of Metastatic Breast Cancer, Dukes C Colon Cancer or Metastatic Colorectal Cancer under fed condition and to assess the bioequivalence.Timepoint: NIL Study Design: Randomized, Crossover Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:An Open list of random numbers Blinding and masking:Open Label

| 2573271 | ecrin-mdr-crc

A Clinical trial intended to compare two formulations of Capecitabine tablets, in patients with Breast Cancer, Dukes C Colon Cancer or Colorectal Cancer.

Project description:Intervention1: XELODAÂ -Capecitabine 500 mg tablets: Capecitabine 1250 mg/m2 administered twice daily orally :BD (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 14 days including of three study periods. Control Intervention1: Capecitabine 500 mg tablets: Capecitabine 1250 mg/m2 administered twice daily orally; BD morning and evening; equivalent to 2500 mg/m2 total daily dose for 14 days including of three study periods. Primary outcome(s): To characterize the pharmacokinetic profile of the sponsors test formulation (Capecitabine Tablets 500 mg, Manufactured by Cadila Heathcare Limited, India) relative to that of reference formulation (XELODAÂ 500 mg tablets, Manufactured by Genentech USA Inc. USA) in patients of Metastatic Breast Cancer, Dukes C Colon Cancer or Metastatic Colorectal Cancer under fed condition and to assess the bioequivalence.Timepoint: Time points are 30 minutes prior to drug dosing and at 0.25hr, 0.50hr, 1hr, 1.5hr, 2hr, 2.5hr, 3hr, 4hr, 5hr, 6hr, 8hr and 10 hours post-dose. Study Design: Randomized, Crossover Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:An Open list of random numbers Blinding and masking:Open Label

| 2573937 | ecrin-mdr-crc

Bioequivalence study of Capecitabine 500 mg with XelodaÂ(capecitabine) tablets 500 mg in Locally Advanced Breast Cancer or Metastatic Breast Cancer or Colorectal Cancer patients under fed condition

Project description:Intervention1: Capecitabine Tablets 500mg: Capecitabine Tablets 500 mg will be administered as a single oral dose as multiples of 500mg on Day 1 and Day 2 morning dose as per randomization schedule. Control Intervention1: Xeloda tablet 500mg: Capecitabine Tablets 500 mg will be administered as a single oral dose as multiples of 500mg on Day 1 and Day 2 morning dose as per randomization schedule. Primary outcome(s): To characterise the pharmacokinetic profile of the sponsors test formulation [Capecitabine Tablets 500 mg] relative to that of reference formulation [XelodaÂ Tablets 500 mg] in patients with Metastatic Breast Cancer or Colorectal Cancer under fed condition and to assess the bioequivalence.Timepoint: The venous blood samples will be withdrawn Pre-dose and 0.25(15 min), 0.5(30 min), 1, 1.333, 1.667, 2, 2.333, 2.667, 3, 3.5, 4, 5, 6, 8, 10 hr post-dose in each period administration

| 2573902 | ecrin-mdr-crc

A clinical study to demonstrate bioequivalence between two drugs Xeloda (Reference) and Capecitabine 500 mg Tablets (Test) in cancer patients

Project description:Intervention1: Capecitabine Tablets : Dose & Frequency: 500 mg per day Duration: 3 days (D1, D3, D5) Mode of Administration: Oral Control Intervention1: Capecitabine (Xeloda) Tablets: Dose & Frequency: 500 mg per day Duration: 3 days (D1, D3, D5) Mode of Administration: Oral Primary outcome(s): Establish the bioequivalence of Test vs Reference in relation to the rate and extent of absorption on the basis of the following pharmacokinetic parameters: â?¢Cmax â?¢AUC0tTimepoint: â?¢D1, D3, D5 â?¢D1, D3, D5 Study Design: Other Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Open Label

| 2573355 | ecrin-mdr-crc

To evaluate the bioequivalence of two formulation of capecitabine Tablets 500 mg tablets in patients of Breast Cancer or Colorectal Cancer under fed condition

Project description:Intervention1: Capecitabine Tablets USP 500 mg,Each film -coated tablet contains: Capecitabine USP 500 mg,Manufactured by: Intas Pharmaceuticals Limited, India.: The recommended dose of XELODAÂ is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3 week cycles Control Intervention1: Xeloda® (capecitabine) Tablets 500 mg,Each tablet contains: Capecitabine 500 mg,Distributed by: Roche Laboratories Inc., New Jersey 07110: The recommended dose of XELODA® is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3 week cycles Primary outcome(s): To characterise the pharmacokinetic profile of the sponsors test formulation [Capecitabine Tablets USP 500 mg (Manufactured by: Intas Pharmaceuticals Ltd., India)] relative to that of reference formulation [XelodaÂ (capecitabine) Tablets 500 mg (Distributed by: Roche Laboratories Inc., New Jersey 07110)] in patients of Breast Cancer or Colorectal Cancer under fed condition and to assess the bioequivalenceTimepoint: NIL Study Design: Randomized, Crossover Trial Method of generating randomization sequence:Other Method of allocation concealment:Other Blinding and masking:Open Label

| 2572297 | ecrin-mdr-crc

A Study Comparing Capecitabine Capsule 500 mg (IntasPharmaceuticals Ltd., India) To The Reference Listed Drug XelodaÂ(Capecitabine 500 mg; Roche Pharmaceuticals) In Patients Of BreastCancer Or Colorectal Cancer Under Fed Condition

Project description:Intervention1: Capecitabine Extended Release Capsule 500 mg (Intas Pharma) : Dose: 1250 mg/m2, Frequency: twice daily, Mode of Administration: orally, Duration of treatment: One week Control Intervention1: XelodaÂ (Capecitabine) film coated tablets 500 mg (Roche Pharmaceuticals) : Dose: 1250 mg/m2, Frequency: twice daily, Mode of Administration: orally, Duration of treatment: One week Primary outcome(s): AUCTimepoint: Day 07 and Day 14

| 2577537 | ecrin-mdr-crc

CLARITY study: Expression data from RRMS patients treated with Oral Cladribine versus Placebo at week 96

Project description:The CLARITY trial (NCT00213135) was designed as a double-blind, placebo-controlled study to allow the best comparison of absolute efficacy and safety of oral cladribine in RRMS subjects. 1326 patients with relapsing MS were randomized (1:1:1) to receive cladribine tablets 3.5 mg/kg or 5.25 mg/kg bodyweight or placebo. Gene expression data in whole blood samples at 96 weeks were prepared according to standard Affymetrix protocols Gene expression data in whole blood samples at 96 weeks were available from patients randomized to placebo (n=57), cladribine tablets 3.5 mg/kg (n=62), and cladribine tablets 5.25 mg/kg (n=70).

2023-05-16 | GSE185773 | GEO

To assess the safety and tolerability of a single oral dose of the Capecitabine test and reference formulations

Project description:Intervention1: Capecitabine Tablets 500 mg, manufactured by Hetero labs ltd.: The recommended dose of capacitabine is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3 week cycles Intervention2: Capecitabine Tablets 500 mg,manufactured by Hetero labs ltd.: The recommended dose of capacitabine is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3 week cycles Control Intervention1: XelodaÂ (Capecitabine) Tablets 500 mg (Distributed by Genentech USA, Inc., A Member of the Roche Group, South San Francisco, CA 94080): The recommended dose of XELODAÂ is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3 week cycles Primary outcome(s): Establishing the bioequivalence between test and referenceTimepoint: Day 1 and Day 2

| 2573933 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data